4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Eledon Pharmaceuticals, Inc. (ELDN) operates in the Biotechnology industry and is headquartered in Irvine, United States with about 33 employees. Its market capitalization is roughly $310 million. In the fiscal year ended 2025-12-31, ELDN reported $0M in revenue and ($46M) in net income.
Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It uses its immunology expertise in targeting the CD40 Ligand (CD40L) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS).
Interactive charts & full statements →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | — |
| Operating Income (EBIT) | ($83M) | ($71M) | ($43M) | ($40M) | — |
| Net Income | ($46M) | ($36M) | ($116M) | ($88M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | $0M | — |
| Operating Income (EBIT) | ($21M) | ($22M) | ($19M) | ($25M) | ($18M) | — |
| Net Income | ($39M) | ($10M) | ($18M) | ($11M) | ($6M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | $169M | $177M | $89M | $93M | — |
| Total Liabilities | $88M | $115M | $82M | $9M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive ELDN viewer.
About TickerBase · Data methodology & sources